Loading clinical trials...
Loading clinical trials...
Recombinant Factor IX (BAX 326): A Phase 1/3, Prospective, Controlled, Multicenter Study Evaluating Pharmacokinetics, Efficacy, Safety and Immunogenicity in Previously Treated Patients With Severe or Moderately Severe Hemophilia B
Conditions
Interventions
BAX 326
BeneFIX
Locations
25
Argentina
Rosario, Argentina
Brasília, Brazil
São Paulo, Brazil
Sofia, Bulgaria
Santiago, Chile
Bogotá, Colombia
Start Date
July 29, 2010
Primary Completion Date
May 3, 2012
Completion Date
May 3, 2012
Last Updated
May 20, 2021
NCT06379789
NCT06008938
NCT04645199
NCT07080905
NCT06700096
NCT06312475
Lead Sponsor
Baxalta now part of Shire
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions